Erica Stringer-Reasor, MD

Erica Stringer-Reasor, MD, is an associate professor of medicine and director of the Breast Cancer Program at the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.

Articles by Erica Stringer-Reasor, MD

Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer

ByErica Stringer-Reasor, MD

July 28th 2026

An investigator behind gedatolisib's FDA approval discusses the trial data, dosing, and adverse effects shaping HR+/HER2- breast cancer care.

Erica Stringer-Reasor, MD, on Gedatolisib's FDA Approval in Breast Cancer

ByErica Stringer-Reasor, MD,Sabrina Serani

July 27th 2026

Erica Stringer-Reasor, MD, of UAB, discusses gedatolisib's FDA approval, its dual PI3K/mTOR mechanism, and what's next in HR+/HER2– breast cancer care.

Latest Updated Articles

Erica Stringer-Reasor, MD, on Gedatolisib's FDA Approval in Breast Cancer
July 27th 2026
Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer
July 28th 2026

Erica Stringer-Reasor, MD

Articles by Erica Stringer-Reasor, MD

Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer

Erica Stringer-Reasor, MD, on Gedatolisib's FDA Approval in Breast Cancer

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap

INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC

FDA Expands Sevabertinib Approval to Treatment-Naive HER2-Mutant NSCLC

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment